Aclaris Therapeutics (ACRS) Non-Current Deffered Revenue (2014 - 2026)
Aclaris Therapeutics (ACRS) posted quarterly Non-Current Deffered Revenue of $15.3 million for Q1 2026, down 20.42% year-over-year from $19.2 million in Q1 2025, and down 5.46% quarter-over-quarter from $16.2 million in Q4 2025.
Aclaris Therapeutics (ACRS) Non-Current Deffered Revenue (2014 - 2026) Analysis & Trends
Aclaris Therapeutics' Non-Current Deffered Revenue history runs 5 years deep, the most recent figure standing at $15.3 million for Q1 2026.
- In Q1 2026, Non-Current Deffered Revenue fell 20.42% year-over-year to $15.3 million; the TTM figure through Mar 2026 stood at $15.3 million (down 20.42% YoY), while the FY2025 annual figure was $16.2 million, down 19.31% from the prior year.
- Non-Current Deffered Revenue for Q1 2026 stood at $15.3 million, down from $16.2 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $21.2 million in Q3 2024, with the low at $15.3 million in Q1 2026.
- The 3-year median for Non-Current Deffered Revenue is $18.2 million (2025), against an average of $18.2 million.
- The sharpest annual moves came in 2025 and 2026: Non-Current Deffered Revenue slipped 17.42% in 2025, then decreased 20.42% in 2026.
- Aclaris Therapeutics' Non-Current Deffered Revenue stood at $20.0 million in 2024, then declined by 19.31% to $16.2 million in 2025, then decreased by 5.46% to $15.3 million in 2026.
- Business Quant data shows ACRS's Non-Current Deffered Revenue at $15.3 million in Q1 2026, $16.2 million in Q4 2025, and $17.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn | 14.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.31 Mn |
| Mar 31, 2026 | 15.29 Mn |
| Dec 31, 2025 | 16.17 Mn |
| Sep 30, 2025 | 17.49 Mn |
| Jun 30, 2025 | 18.22 Mn |
| Mar 31, 2025 | 19.21 Mn |
| Dec 31, 2024 | 20.04 Mn |
| Sep 30, 2024 | 21.18 Mn |
| Sep 30, 2015 | 3,000.00 |
| Dec 31, 2014 | 4,000.00 |